Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
https://doi.org/10.31631/2073-3046-2018-17-3-57-62
Abstract
In this multicenter double blind randomized clinical study with parallel groups conducted with 612 healthy volunteers, domestic influenza quadrivalent inactivated subunit vaccine Grippol® Quadrivalent safety, tolerability and immunogenicity was evaluated in comparison with seasonal trivalent vaccines, It was demonstrated that quadrivalent influenza vaccine Grippol® Quadrivalent possesses good tolerability, low reactogenicity, and has favorable safety profile similar to that for trivalent comparators. Besides, it was proven that quadrivalent influenza vaccine Grippol® Quadrivalent has same immunogenicity for three conventional strains and significantly exceeds trivalent comparators for missed influenza B strain.
About the Authors
D. A. Lioznov
I. P. Pavlov First St. Petersburg State Medical University, St. Petersburg;
Research Institute of Influenza, St. Petersburg
Russian Federation
Dr. Sci. (Med.), associate professor, deputy director for scientific work of Research Institute of Influenza. +7 (812) 499-15-85; head of the department of infectious diseases and epidemiology of the Pavlov First Saint Petersburg State Medical University
Russian Federation
Dr. Sci. (Med.), associate professor, deputy director for scientific work of Research Institute of Influenza. +7 (812) 499-15-85; head of the department of infectious diseases and epidemiology of the Pavlov First Saint Petersburg State Medical University
S. M. Kharit
Pediatric Research and Clinical Center for Infectious Diseases, St. Petersburg
Russian Federation
Dr. Sci. (Med.), professor, head of the department for the prevention of infectious diseases of the children’s Scientific and Clinical Center for Infectious Diseases
Russian Federation
Dr. Sci. (Med.), professor, head of the department for the prevention of infectious diseases of the children’s Scientific and Clinical Center for Infectious Diseases
M. K. Erofeeva
Research Institute of Influenza, St. Petersburg
Russian Federation
Dr. Sci. (Med.), head a laboratory for testing new drugs of protection against viral infections
Russian Federation
Dr. Sci. (Med.), head a laboratory for testing new drugs of protection against viral infections
T. G. Zubkova
Research Institute of Influenza, St. Petersburg
Russian Federation
Cand. Sci. (Med.), head of the consultative and diagnostic department
Russian Federation
Cand. Sci. (Med.), head of the consultative and diagnostic department
O. V. Gorchakova
I. P. Pavlov First St. Petersburg State Medical University, St. Petersburg
Russian Federation
Cand. Sci. (Med.), researcher of the laboratory of chronic viral infections Scientific Research Center
Russian Federation
Cand. Sci. (Med.), researcher of the laboratory of chronic viral infections Scientific Research Center
S. L. Nikolaenko
I. P. Pavlov First St. Petersburg State Medical University, St. Petersburg
Russian Federation
Cand. Sci. (Med.), senior researcher of the laboratory of chronic viral infections Scientific Research Center
Russian Federation
Cand. Sci. (Med.), senior researcher of the laboratory of chronic viral infections Scientific Research Center
References
1. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. Vaccine. 2010; 28 (Suppl 4: D45-53). doi: 10.1016/j.vaccine.2010.08.028.
2. Russell CA., Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza virus. Vaccine (2008); 26 (Suppl. 4): D31-4. doi: 10.1016/j.vaccine.2008.07.078.
3. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Virology. 1990; 175: 59–69. DOI: 10.1016/0042-6822(90)90186-u.
4. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X... Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine. 2010; 28: 2149–56.
5. Couch RB. Background and presentation of possible vaccine options. Presented at: Food and Drug administration, Center of Biologics evaluation and research, vaccines and related biological products. Advisory Committee meeting: February 27 – 28, 2007; Washington, DC.
6. US Centers for Disease control and prevention. Seasonal influenza activity surveillance reports: 1999–2000 to 2010–2011 seasons. Доступно на/Available at: «http:// www.cdc.gov/flu/weekly/pastreports.htm%20Accessed%20November%2017», 2011.
7. World Health Organization. WHO/Europe influenza surveillance. Доступно на/Available at: http://www.euroflu.org/index.php. Accessed June 20, 2011.
8. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human vaccines& Immunotherapeutics 2012; 1: 81–88.
9. Dijkstra F, Donker GA, Wilbrink B, van Gageldonk-Lafeber AB, van Der Sande MA B. Long time trends in influenza-like illness and associated determinants in the Netherlands. Epidemiological Infections 2009; 137: 473 –9.
10. Heikkinen T, Ikonen N, Ziegler Th. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating visuses, 1999–2012. CID 2014: 59.
11. WHO. Vaccine Position Papers. Доступно на/Available at: http://www.who.int/wer/2012/wer.
Review
For citations:
Lioznov D.A., Kharit S.M., Erofeeva M.K., Zubkova T.G., Gorchakova O.V., Nikolaenko S.L. Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine. Epidemiology and Vaccinal Prevention. 2018;17(3):57-62. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-3-57-62
Views:
992
Email this article 